Company intelligence / Profile preview

TargaGenix

Stony Brook, New York, United States

Ownership: Private
Development stage: Other

Overview

TargaGenix is developing DHA-SBT-1214, a third-generation taxane designed to target cancer stem cells and chemotherapy-resistant tumors. Preclinical data shows potent anti-tumor activity in animal models, with improved pharmacokinetics and significant tumor suppression vs. standard therapies. Combination with anti–PD-L1 antibody demonstrates enhanced efficacy in pancreatic cancer models.

Therapeutic areas: Oncology
Modalities: Small molecule drugNanoparticle
Industry: Biotech

Partnerships

Stony Brook University

Beyond the preview

Go deeper on TargaGenix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TargaGenix.

Explore the full profile